Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kenneth W Mahaffey

Showing results (461-470 of 636) with videos related to

Pageof 64
Sort By:
European Heart Journal. Acute Cardiovascular Care|August 4, 2016
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experienceSergio Leonardi, Renato D Lopes, Ph Gabriel Steg, et al.
American Heart Journal|September 21, 2015
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 25, 2015
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxarJean-Pierre Déry, Kenneth W Mahaffey, Pierluigi Tricoci, et al.
American Heart Journal|March 21, 2016
Pooled analysis of adverse event collection from 4 acute coronary syndrome trialsAndré Zimerman, Renato D Lopes, Amanda L Stebbins, et al.
Vascular Medicine (London, England)|July 12, 2018
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trialJeffrey S Berger, Beth L Abramson, Renato D Lopes, et al.
Circulation|November 21, 2007
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trialPierluigi Tricoci, Yuliya Lokhnygina, Lisa G Berdan, et al.
European Heart Journal|March 27, 2013
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trialSergio Leonardi, Pierluigi Tricoci, Harvey D White, et al.
American Heart Journal|March 18, 2020
Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillationFrederik Dalgaard, Rebecca North, Karen Pieper, et al.
JAMA Cardiology|November 29, 2018
Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation IIUtibe R Essien, DaJuanicia N Holmes, Larry R Jackson, et al.
American Heart Journal|July 29, 2014
Independent data monitoring committees: preparing a path for the futureConnie N Hess, Matthew T Roe, C Michael Gibson, et al.
Pageof 64

Showing results (461-470 of 636) with videos related to

Sort By:
Pageof 64
European Heart Journal. Acute Cardiovascular Care|August 4, 2016
Implications of different criteria for percutaneous coronary intervention-related myocardial infarction on study results of three large phase III clinical trials: The CHAMPION experienceSergio Leonardi, Renato D Lopes, Ph Gabriel Steg, et al.
American Heart Journal|September 21, 2015
Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: the Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)Sameer Bansilal, Zachary Bloomgarden, Jonathan L Halperin, et al.
Catheterization and Cardiovascular Interventions : Official Journal of the Society for Cardiac Angiography & Interventions|December 25, 2015
Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxarJean-Pierre Déry, Kenneth W Mahaffey, Pierluigi Tricoci, et al.
American Heart Journal|March 21, 2016
Pooled analysis of adverse event collection from 4 acute coronary syndrome trialsAndré Zimerman, Renato D Lopes, Amanda L Stebbins, et al.
Vascular Medicine (London, England)|July 12, 2018
Ticagrelor versus clopidogrel in patients with symptomatic peripheral artery disease and prior coronary artery disease: Insights from the EUCLID trialJeffrey S Berger, Beth L Abramson, Renato D Lopes, et al.
Circulation|November 21, 2007
Time to coronary angiography and outcomes among patients with high-risk non ST-segment elevation acute coronary syndromes: results from the SYNERGY trialPierluigi Tricoci, Yuliya Lokhnygina, Lisa G Berdan, et al.
European Heart Journal|March 27, 2013
Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trialSergio Leonardi, Pierluigi Tricoci, Harvey D White, et al.
American Heart Journal|March 18, 2020
Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillationFrederik Dalgaard, Rebecca North, Karen Pieper, et al.
JAMA Cardiology|November 29, 2018
Association of Race/Ethnicity With Oral Anticoagulant Use in Patients With Atrial Fibrillation: Findings From the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation IIUtibe R Essien, DaJuanicia N Holmes, Larry R Jackson, et al.
American Heart Journal|July 29, 2014
Independent data monitoring committees: preparing a path for the futureConnie N Hess, Matthew T Roe, C Michael Gibson, et al.
Pageof 64